MedTrace Logo

Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes

NCT02827630 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2016-07-11

No results posted yet for this study

Summary

The purpose of this study was to evaluate the efficacy of a new digital health offering, Proteus Discover to lower blood pressure and glycated hemoglobin in patients with uncontrolled hypertension and type 2 diabetes.

Conditions

Interventions

OTHER

Proteus Discover

FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application

OTHER

Usual Care

Routine medical care including medication titration, adherence counseling, and lifestyle coaching.

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Proteus Digital Health, Inc.

    lead INDUSTRY

Principal Investigators

  • Lars Osterberg, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-11-30
Completion
2016-01-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02827630 on ClinicalTrials.gov